MoonLake Immunotherapeutics expected to post a loss of 27 cents a share - Earnings Preview

MoonLake Immunotherapeutics

10/05/2024 13:16

* MoonLake Immunotherapeutics  MLTX.OQ   MLTX.O  is expected
to show no change in quarterly revenue when it reports 
results on August 8 (estimated) for the period ending June
30 2024
    * 
    * ​LSEG's mean analyst estimate for MoonLake
Immunotherapeutics is
for a loss of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 25.3%
in the last three months. ​
    * Wall Street's median 12-month price target for MoonLake
Immunotherapeutics is $71.50​, above​ its last closing price
of $41.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.17       -0.19      -0.22     Missed  -13.8
 Jan. 1 2024   -0.20       -0.23      -0.12     Beat    47.9
 Sep. 30 2023  -0.22       -0.23      -0.18     Beat    20.9​
 Jun. 30 2023  -0.27       -0.27      -0.23     Beat    13.4
 ​​Mar.        -0.30       -0.31      -0.23     Beat    25.9
 31 2023                                                
 Dec. 31 2022  -0.34       -0.33      -0.31     Beat    5.3​
 Sep. 30 2022  -0.32       -0.32      -0.27     Beat    15.8
 Jun. 30 2022  -0.55       -0.54      -0.34     Beat    37
 This summary was machine generated May 10 at 12:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)